Table 1.
Clinical characteristics from patients with cutaneous lupus erythematosus.
| Cutaneous lupus erythematosus | Healthy donor | P value | ||
|---|---|---|---|---|
| SCLE n = 22 | DLE n = 20 | n = 19 | ||
| Demographics | ||||
| Age (years) | ||||
| Mean ± SD | 38.2 ± 13.6 | 37.4 ± 15.3 | 43.6 ± 16.5 | |
| Median | 34.5 | 32.5 | 45.0 | |
| Range | (20-62) | (18-74) | (21-76) | |
| Sex, females, (%) | 95.5 | 95 | 95 | |
| Disease duration (years) | ||||
| Mean ± SD | 10.2 ± 10.3 | 7.5 ± 6.4 | – | |
| Median | 6.0 | 7.0 | ||
| Range | (1-41) | (1-26) | ||
| Laboratory variables | ||||
| Hemoglobin (g/dl) | ||||
| Mean ± SD | 12.6 ± 2.0 | 13.4 ± 1.5 | 14.4 ± 1.0 | |
| Median | 13.0 | 13.2 | 14.5 | |
| Range | (9.3–15.8) | (11.2–16.5) | (12.5–15.8) | |
| Leucocytes (cells/μl) | ||||
| Mean ± SD | 4905 ± 1951 | 4944 ± 1311 | 5649 ± 2102 | |
| Median | 4900 | 4900 | 5500 | |
| Range | (1700–9100) | (2400–7000) | (1140–8200) | |
| Lymphocytes (%) | ||||
| Mean ± SD | 19.1 ± 7.44 | 21.9 ± 5.2 | 30.4 ± 10.6 | |
| Median | 19.0 | 22.7 | 29.9 | |
| Range | (8.0–33.0) | (14.9–33.5) | (18.1–47.2) | |
| Monocytes (%) | ||||
| Mean ± SD | 9.3 ± 3.7 | 7.7 ± 2.6 | 6.8 ± 2.7 | |
| Median | 9.1 | 8.2 | 6.7 | |
| Range | (4.4 – 15.0) | (3.0 – 13.1) | (1.0 – 10.3) | |
| Neutrophils (%) | ||||
| Mean ± SD | 70.6 ± 8.3 | 68.1 ± 6.5 | 59.4 ± 10.7 | |
| Median | 72.6 | 67.6 | 62.5 | 0.003 |
| Range | (53.0–82.7) | (53.6–8.8) | (43.5–73.3) | |
| Platelets (x103cells/μl) | ||||
| Mean ± SD | 191.6 ± 83.1 | 204.9 ± 49.4 | 241.8 ± 34.9 | |
| Median | 205.0 | 223.5 | 249.0 | |
| Range | (30–360) | (128–276) | (192–306) | |
| C3 (mg/dl) | – | |||
| Mean ± SD | 73.2 ± 31.8 | 82.3 ± 28.1 | ||
| Median | 68.5 | 78.7 | ||
| Range | (29.4-130.4) | (28.8-132.4) | ||
| C4 (mg/dl) | – | |||
| Mean ± SD | 16.4 ± 9.9 | 15.2 ± 5.9 | ||
| Median | 13.5 | 14.3 | ||
| Range | (5.9-37.2) | (6.0-29.0) | ||
| Anti-dsDNA (IU/ml) | – | |||
| Mean ± SD | 135.6 ± 188.3 | 234.4 ± 363.5 | ||
| Median | 49.0 | 12.5 | ||
| Range | (12.3-570.0) | (7.7-1116.7) | ||
| Clinical variables | ||||
| CLASI activity score | – | 0.01 | ||
| Mean ± SD | 20.9 ± 8.2 | 13.4 ± 6.3 | ||
| Median | 20.0 | 12.5 | ||
| Range | (9-37) | (2-29) | ||
| Treatment | ||||
| Antimalarial (%) | 14 (63.6) | 13 (65) | – | |
| Prednisone (mg/day) | 10 | 15 | – | |
| Immunosuppressants (%) | 13 (59) | 12 (60) | – | |